Early Access — free while we kick the tires
EdgarHawk

Bruns Ingmar

Chief Medical Officer

Officer
1 filing analyzed · 1 company · Latest 2025-02-12

Companies

Company Buys Sells Direction
Zentalis Pharmaceuticals, Inc. ZNTL 1 0 Net buying

Activity

February 2025
Buy
20,000 shares
$45,656
Significance 6/10

CMO Bruns Ingmar bought 20,000 shares of ZNTL at $2.28; stock now $2.16, down 86.6% from 52-week high

Chief Medical Officer Bruns Ingmar purchased 20,000 shares at $2.28 on 2025-02-06, more than doubling his post-transaction holdings to 36,629 shares from 16,629 shares. The stock is trading at a steep discount to its 52-week high of $16.13, currently down 86.6% from that peak and off 15.6% over the past 30 days. The company generated no revenue in its latest quarter and reported a net loss of $40,158,000.00, with unprofitability across its most recent full fiscal year. Notably, this purchase is part of a cluster pattern with 3 other insiders also buying within the past 14 days, suggesting coordinated action by company leadership during a period of severe stock decline and operational losses.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access